Summit Therapeutics PLC Company Profile (LON:SUMM)

About Summit Therapeutics PLC (LON:SUMM)

Summit Therapeutics PLC logoSummit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:SUMM
  • CUSIP: N/A
  • Web: www.summitplc.com/
Capitalization:
  • Market Cap: £117.63 million
  • Outstanding Shares: 61,908,000
Average Prices:
  • 50 Day Moving Avg: GBX 179.63
  • 200 Day Moving Avg: GBX 183.43
  • 52 Week Range: GBX 88 - GBX 262
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £4.05 million
  • Price / Sales: 29.04
  • Book Value: GBX (0.13) per share
  • Price / Book: -14.62
Profitability:
  • EBIDTA: ($24,350,000.00)
  • Net Margins: -275.52%
  • Return on Assets: -55.76%
Misc:
  • Average Volume: 34,980 shs.
 
Frequently Asked Questions for Summit Therapeutics PLC (LON:SUMM)

What is Summit Therapeutics PLC's stock symbol?

Summit Therapeutics PLC trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

When will Summit Therapeutics PLC make its next earnings announcement?

Summit Therapeutics PLC is scheduled to release their next quarterly earnings announcement on Wednesday, September, 6th 2017. View Earnings Estimates for Summit Therapeutics PLC.

Who are some of Summit Therapeutics PLC's key competitors?

Who are Summit Therapeutics PLC's key executives?

Summit Therapeutics PLC's management team includes the folowing people:

  • Glyn Edwards, Chief Executive Officer, Executive Director
  • Erik Ostrowski, Chief Financial Officer
  • David Roblin, Chief Operating Officer, President - Research and Development
  • Ralf H. Rosskamp M.D., Chief Medical Officer
  • Frank Murdoch Armstrong, Non-Executive Chairman of the Board
  • Valerie L. Andrews, Non-Executive Director
  • Stephen J. Davies, Non-Executive Director
  • Barry J. Price Ph.D., Non-Executive Director
  • David Wurzer CPA, Non-Executive Director

How do I buy Summit Therapeutics PLC stock?

Shares of Summit Therapeutics PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Summit Therapeutics PLC's stock price today?

One share of Summit Therapeutics PLC stock can currently be purchased for approximately GBX 190.


MarketBeat Community Rating for Summit Therapeutics PLC (LON SUMM)
Community Ranking:  1.4 out of 5 ()
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (LON:SUMM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Summit Therapeutics PLC (LON:SUMM)
Show:
DateFirmActionRatingPrice TargetDetails
6/15/2017N+1 SingerReiterated RatingcorporateView Rating Details
(Data available from 7/24/2015 forward)

Earnings

Earnings History for Summit Therapeutics PLC (LON:SUMM)
Earnings by Quarter for Summit Therapeutics PLC (LON:SUMM)
Earnings History by Quarter for Summit Therapeutics PLC (LON SUMM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/6/2017N/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Summit Therapeutics PLC (LON:SUMM)
Current Year EPS Consensus Estimate: $-38.45 EPS

Dividends

Dividend History for Summit Therapeutics PLC (LON:SUMM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Summit Therapeutics PLC (LON:SUMM)
Insider Trades by Quarter for Summit Therapeutics PLC (LON:SUMM)
Insider Trades by Quarter for Summit Therapeutics PLC (LON:SUMM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/17/2015Valerie AndrewsInsiderBuy10,500GBX 145£15,225
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Summit Therapeutics PLC (LON:SUMM)
Latest Headlines for Summit Therapeutics PLC (LON:SUMM)
Source:
DateHeadline
nasdaq.com logoSarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View - Nasdaq
www.nasdaq.com - July 21 at 7:31 AM
bizjournals.com logoGlobal Antibiotics Technologies, Markets, Competitors and Opportunities 2017-2022: The Quest for New Super Drugs
www.bizjournals.com - July 13 at 10:04 AM
nasdaq.com logoCan Summit Therapeutics (SMMT) Run Higher on Strong Earnings ... - Nasdaq
www.nasdaq.com - July 4 at 3:40 PM
finance.yahoo.com logoSummit Therapeutics plc : Exercise of Share Options
finance.yahoo.com - June 29 at 7:06 AM
finance.yahoo.com logoSummit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : June 26, 2017
finance.yahoo.com - June 27 at 8:46 AM
finance.yahoo.com logoSummit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q1, 2018 By the Numbers : June 23, 2017
finance.yahoo.com - June 24 at 7:03 AM
finance.yahoo.com logoSummit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress
finance.yahoo.com - June 22 at 1:54 PM
morningstar.co.uk logoSummit Therapeutics Quarterly Loss Narrows On Milestone Revenue
www.morningstar.co.uk - June 15 at 10:13 PM
reuters.com logoBRIEF-Summit Therapeutics Plc Q1 loss £4.8 million
www.reuters.com - June 15 at 10:13 PM
americanbankingnews.com logoN+1 Singer Reiterates "corporate" Rating for Summit Therapeutics PLC (SUMM)
www.americanbankingnews.com - June 15 at 9:48 AM
lse.co.uk logoSummit Therapeutics plc : Notice of Results - London South East (registration) (blog)
www.lse.co.uk - June 15 at 1:33 AM
nasdaq.com logoSummit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017 - Nasdaq
www.nasdaq.com - June 15 at 1:33 AM
reuters.com logoBRIEF-Summit Therapeutics Plc Q1 loss £4.8 million - Reuters
www.reuters.com - June 15 at 1:33 AM
finance.yahoo.com logoSummit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SUMM-GB : June 8, 2017
finance.yahoo.com - June 9 at 1:27 AM
finance.yahoo.com logoSummit Announces Key Appointments to Strengthen Research and Development Team
finance.yahoo.com - May 23 at 9:03 AM
finance.yahoo.com logoSummit Announces Key Appointments to Strengthen Research & Development Team
finance.yahoo.com - May 23 at 9:03 AM
americanbankingnews.com logoSummit Therapeutics PLC's (SUMM) " Corporate" Rating Reiterated at N+1 Singer
www.americanbankingnews.com - May 16 at 8:28 AM
morningstar.co.uk logoSummit Therapeutics Gets USD22 Million Milestone As Enrolment Complete
www.morningstar.co.uk - May 15 at 9:07 AM
finance.yahoo.com logoSummit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD
finance.yahoo.com - May 15 at 9:07 AM
americanbankingnews.com logoSummit Therapeutics PLC (SUMM) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 5:02 AM
finance.yahoo.com logoSummit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases
finance.yahoo.com - May 2 at 9:09 AM
globenewswire.com logoPhase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit's Ridinilazole ... - GlobeNewswire (press release)
globenewswire.com - April 28 at 8:51 PM
finance.yahoo.com logoPhase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
finance.yahoo.com - April 28 at 8:51 PM
globenewswire.com logoSummit Therapeutics plc : Notice of AGM - GlobeNewswire (press release)
globenewswire.com - April 25 at 9:34 AM
finance.yahoo.com logoSummit Therapeutics plc : Notice of AGM
finance.yahoo.com - April 25 at 9:34 AM
finance.yahoo.com logoSummit Therapeutics plc : Grant of Share Options
finance.yahoo.com - April 12 at 12:49 PM
finance.yahoo.com logoSummit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q4, 2017 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 12:51 PM
globenewswire.com logoSummit Therapeutics plc : Change of Registered Office - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:21 PM
finance.yahoo.com logoSummit Therapeutics File US Annual Report on Form 20-F
finance.yahoo.com - March 31 at 3:21 PM
morningstar.co.uk logoSummit Therapeutics Annual Loss Widens As It Progresses Pipeline
www.morningstar.co.uk - March 30 at 8:43 PM
finance.yahoo.com logoSummit Therapeutics plc : Change of Registered Office
finance.yahoo.com - March 30 at 8:43 PM
americanbankingnews.com logoN+1 Singer Reaffirms "corporate" Rating for Summit Therapeutics PLC (SUMM)
www.americanbankingnews.com - March 30 at 11:50 AM
globenewswire.com logoSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and ... - GlobeNewswire (press release)
globenewswire.com - March 29 at 8:01 AM
finance.yahoo.com logoSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
finance.yahoo.com - March 29 at 8:01 AM
finance.yahoo.com logoSummit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress
finance.yahoo.com - March 29 at 8:01 AM
biz.yahoo.com logoFull Year 2017 Summit Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - March 29 at 8:01 AM
reuters.com logoBRIEF-Summit to extend ongoing trial of Ezutromid in patients with Duchenne disorder
www.reuters.com - March 27 at 7:15 PM
finance.yahoo.com logoSummit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD
finance.yahoo.com - March 27 at 8:57 AM
finance.yahoo.com logoSummit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
finance.yahoo.com - March 15 at 8:20 AM
finance.yahoo.com logoSummit Therapeutics Recognises 10th Annual Rare Disease Day
finance.yahoo.com - February 28 at 11:42 AM
finance.yahoo.com logoSummit Therapeutics Recognises Tenth Annual Rare Disease Day
finance.yahoo.com - February 28 at 11:42 AM
lse.co.uk logoSUMMIT THERAPEUTICS TO PARTICIPATE IN FEBRUARY INVESTOR CONFERENCES - London South East (registration) (blog)
www.lse.co.uk - February 3 at 6:03 AM
streetinsider.com logoForm 6-K Summit Therapeutics plc For: Feb 01 - StreetInsider.com
www.streetinsider.com - February 3 at 6:03 AM
globenewswire.com logoSummit Therapeutics plc : 3rd Quarter Results - GlobeNewswire (press release)
globenewswire.com - December 16 at 5:07 AM
biz.yahoo.com logoQ3 & 9M 2017 Summit Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - December 16 at 5:07 AM
finance.yahoo.com logoSummit Therapeutics plc : Notice of Results
finance.yahoo.com - December 14 at 5:02 AM
finance.yahoo.com logoSummit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society
finance.yahoo.com - October 6 at 11:25 AM
finance.yahoo.com logoSarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - October 4 at 11:04 AM
finance.yahoo.com logoSummit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - October 4 at 11:03 AM
uk.finance.yahoo.com logoBUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal
uk.finance.yahoo.com - October 4 at 11:03 AM

Social

Social activity is not available for this stock.

Chart

Summit Therapeutics PLC (SUMM) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff